Skip to content

Science Pulse

at Proud ScientistECG · AP · GW

Forum · Medicine · Story discussion

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At…

2 days ago — MedPage Today · Read the original

Peer reviews (0)

Comments (0)

No comments yet. Start the discussion.

Loading sign-in…